Entity family

Browse drugs

Named medicines, compounds, vaccines, and pharmacological agents. Examples include metformin, semaglutide, antibiotics.

4articles mentioning drugs

28drug mentions

1distinct drugs extracted

0%of mentions human-reviewed

Active filtersEntity: HM16390 ×

HM16390

This drug is selected. Its supporting articles are shown below.

Articles mentioning HM16390

4 articles · page 1 of 1

850 HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ binding and optimal IL-2Rα binding, selectively expands tumor-specific T cells, resulting in potent anti-tumor immunity in murine tumor models

jitc · abstract · 2025-11-04 · 10 matching annotations

98.4%

HM16390 paclitaxel non-alpha variant MC38 tumors C57BL/6 mice

…in only marginal tumor control (<40% TGI) without achieving CR. HM16390 elicited an improved, yet still insufficient, anti-tumor activi…

539 A Phase I, open-label, multicenter, dose escalation and expansion study of HM16390, as a single agent and in combination with pembrolizumab, in patients with advanced or metastatic solid tumors

jitc · abstract · 2025-11-04 · 8 matching annotations

98.7%

HM16390 pembrolizumab vascular leak syndrome cytokine release syndrome Arm A Arm B

…n while modulating immunosuppressive regulatory T cell (T reg). HM16390 is a novel, long-acting IL-2 analog engineered with precise bin…

859 HM16390, a long-acting IL-2 analog with enhanced IL-2Rβ and optimal IL-2Rα bindings, promotes peripheral Treg expansion to mitigate systemic toxicity while preserving potent anti-tumor immunity

jitc · abstract · 2025-11-04 · 7 matching annotations

97.8%

HM16390 IL-2 analogs

…ith poor tolerability and lethality at high doses. In contrast, HM16390 induced a dose-dependent increase in Tregs, which appeared to s…

137 Identifying predictive biomarkers for HM16390, a novel long-acting IL-2 analog, by analyzing single-cell and bulk transcriptomic data of immune checkpoint inhibitors treated patients

jitc · abstract · 2025-11-04 · 3 matching annotations

96.2%

HM16390 cancer immunotherapy

…cy is still limited without appropriate patient stratification. HM16390 is an IL-2 analog engineered with enhanced IL-2Rβ binding and f…